Chemical-specific screening criteria for interpretation of biomonitoring data for volatile organic compounds (VOCs) - Application of steady-state PBPK model solutions

Regulatory Toxicology and Pharmacology

Volumn 58, Issue 1, 2010, Pages 33-44

  Aylward, Lesa L ^a   Kirman, Chris R ^a   Blount, Ben C ^b   Hays, Sean M ^a  

^a LLP   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Biomonitoring; Pharmacokinetic models; Risk assessment; Volatile organic compounds

Indexed keywords

VOLATILE ORGANIC COMPOUND;

ARTICLE; BIOLOGICAL MONITORING; BLOOD LEVEL; CANCER RISK; CHEMICAL ANALYSIS; CHEMICAL MODEL; CHEMICAL PARAMETERS; ENVIRONMENTAL EXPOSURE; INHALATION; MATHEMATICAL ANALYSIS; PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL; PRIORITY JOURNAL; REFERENCE VALUE; RISK ASSESSMENT; STEADY STATE;

ANIMALS; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL MONITORING; ENVIRONMENTAL POLLUTANTS; ENVIRONMENTAL POLLUTION; HUMANS; MODELS, CHEMICAL; NUTRITION SURVEYS; RATS; RISK ASSESSMENT; RISK FACTORS; VOLATILE ORGANIC COMPOUNDS;

EID: 77955920291     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2010.05.011     Document Type: Article

References (38)

1. Adams J.C., Dills R.L., Morgan M.S., Kalman D.A., Pierce C.H. A physiologically based toxicokinetic model of inhalation exposure to xylenes in Caucasian men. Regul. Toxicol. Pharmacol. 2005, 43:203-214.
2. Aylward L.L., Barton H.A., Hays S.M. Biomonitoring Equivalents (BE) dossier for toluene (CAS No. 108-88-3). Regul. Toxicol. Pharmacol. 2008, 51:S27-S36.
3. Aylward L.L., LaKind J.S., Hays S.M. Biomonitoring Equivalents (BE) dossier for trihalomethanes. Regul. Toxicol. Pharmacol. 2008, 51:S68-S77.
4. Baars A.J., Theelen R.M.C., Janssen P.J.C.M., Hesse J.M., van Apeldoorn M.E., Meijerink M.C.M., Verdam L., Zeilmaker M.J. Re-Evaluation of Human-Toxicological Maximum Permissible Risk Levels. RIVM Report 711701 025 2001, Dutch National Institute of Public Health and the Environment, Bilthoven, Netherlands.
5. Brown E.A., Shelley M.L., Fisher J.W. A pharmacokinetic study of occupational and environmental benzene exposure with regard to gender. Risk Anal. 1998, 18:205-213.
6. Brown R.P., Delp M.D., Lindstedt S.L., Rhomberg L.R., Beliles R.P. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Health 1997, 13:407-484.
7. Centers for Disease Control, Prevention (CDC) Third National Report on Human Exposure to Environmental Chemicals 2005, Department of Health and Human Services, Atlanta, GA.
8. Chiu W.A., White P. Steady-state solutions to PBPK models and their applications to risk assessment I: route-to-route extrapolation of volatile chemicals. Risk Anal. 2006, 26:769-780.
9. Covington T.R., Robinan Gentry P., Van Landingham C.B., Andersen M.E., Kester J.E., Clewell H.J. The use of Markov chain Monte Carlo uncertainty analysis to support a Public Health Goal for perchloroethylene. Regul. Toxicol. Pharmacol. 2007, 47:1-18.
10. Droz P.O., Berode M., Jang J.Y. Biological monitoring of tetrahydrofuran: contribution of a physiologically based pharmacokinetic model. Am. Ind. Hyg. Assoc. J. 1999, 60:243-248.
11. Gargas M.L., Andersen M.E. Determining kinetic constants of chlorinated ethane metabolism in the rat from rates of exhalation. Toxicol. Appl. Pharmacol. 1989, 99:344-353.
12. Gargas M.L., Burgess R.J., Voisard D.E., Cason G.H., Andersen M.E. Partition coefficients of low-molecular-weight volatile chemicals in various liquids and tissues. Toxicol. Appl. Pharmacol. 1989, 98:87-99.
13. Gargas M.L., Clewell H.J., Andersen M.E. Gas uptake inhalation techniques and rates of metabolism of chloromethanes, chloroethanes, and chloroethylenes in the rat. Inhal. Toxicol. 1990, 2:295-319.
14. Haddad S., Tardif G.C., Tardif R. Development of physiologically based toxicokinetic models for improving the human indoor exposure assessment to water contaminants: trichloroethylene and trihalomethanes. J. Toxicol. Environ. Health A 2006, 69:2095-2136.
15. Hays S.M., Aylward L.L., LaKind J.S., Bartels M.J., Barton H.A., Boogaard P.J., Brunk C., DiZio S., Dourson M., Goldstein D.A., Lipscomb J., Kilpatrick M.E., Krewski D., Krishnan K., Nordberg M., Okino M., Tan Y.M., Viau C., Yager J.W. Guidelines for the derivation of Biomonitoring Equivalents: report from the Biomonitoring Equivalents Expert Workshop. Regul. Toxicol. Pharmacol. 2008, 51:S4-S15.
16. Hays S.M., Becker R.A., Leung H.W., Aylward L.L., Pyatt D.W. Biomonitoring equivalents: a screening approach for interpreting biomonitoring results from a public health risk perspective. Regul. Toxicol. Pharmacol. 2007, 47:96-109.
17. Hissink A.M., Van Ommen B., Kruse J., Van Bladeren P.J. A physiologically based pharmacokinetic (PB-PK) model for 1, 2-dichlorobenzene linked to two possible parameters of toxicity. Toxicol. Appl. Pharmacol. 1997, 145:301-310.
18. Hissink A.M., Wormhoudt L.W., Sherratt P.J., Hayes J.D., Commandeur J.N., Vermeulen N.P., van Bladeren P.J. A physiologically-based pharmacokinetic (PB-PK) model for ethylene dibromide: relevance of extrahepatic metabolism. Food Chem. Toxicol. 2000, 38:707-716.
19. Kedderis G.L., Held S.D. Prediction of furan pharmacokinetics from hepatocyte studies: comparison of bioactivation and hepatic dosimetry in rats, mice, and humans. Toxicol. Appl. Pharmacol. 1996, 140:124-130.
20. Kroes R., Kleiner J., Renwick A. The threshold of toxicological concern concept in risk assessment. Toxicol. Sci. 2005, 86:226-230.
21. LaKind J.S., Aylward L.L., Brunk C., DiZio S., Dourson M., Goldstein D.A., Kilpatrick M.E., Krewski D., Bartels M.J., Barton H.A., Boogaard P.J., Lipscomb J., Krishnan K., Nordberg M., Okino M., Tan Y.M., Viau C., Yager J.W., Hays S.M. Guidelines for the communication of Biomonitoring Equivalents: report from the Biomonitoring Equivalents Expert Workshop. Regul. Toxicol. Pharmacol. 2008, 51:S16-S26.
22. Liao K.H., Tan Y.M., Clewell H.J. Development of a screening approach to interpret human biomonitoring data on volatile organic compounds: reverse dosimetry on biomonitoring data for trichloroethylene. Risk Anal. 2007, 27:1223-1236.
23. Licata A.C., Dekant W., Smith C.E., Borghoff S.J. A physiologically based pharmacokinetic model for methyl tert-butyl ether in humans: implementing sensitivity and variability analyses. Toxicol. Sci. 2001, 62:191-204.
24. Lipscomb J.S., Poet T.S. In vitro measurements of metabolism for application in pharmacokinetic modeling. Pharmacol. Ther. 2008, 118:82-103.
25. Meek M.E., Renwick A., Ohanian E., Dourson M., Lake B., Naumann B.D., Vu V. Guidelines for application of chemical-specific adjustment factors in dose/concentration-response assessment. Toxicology 2002, 181-182:115-120.
26. Nong A., Krishnan K. Estimation of interindividual pharmacokinetic variability factor for inhaled volatile organic chemicals using a probability-bounds approach. Regul. Toxicol. Pharmacol. 2007, 48:93-101.
27. Pelekis M., Krewski D., Krishnan K. Physiologically based algebraic expressions for predicting steady-state toxicokinetics of inhaled vapors. Toxicol. Methods 1997, 7:205-225.
28. Perleberg U.R., Keys D.A., Fisher J.W. Development of a physiologically based pharmacokinetic model for decane, a constituent of jet propellent-8. Inhal. Toxicol. 2004, 16:771-783.
29. Price P.S., Conolly R.B., Chaisson C.F., Gross E.A., Young J.S., Mathis E.T., Tedder D.R. Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit. Rev. Toxicol. 2003, 33:469-503.
30. Saghir S.A., Rick D.L. Simulation of repeated dose kinetics of methyl isobutyl ketone in humans from experimental single-dose inhalation exposure. Regul. Toxicol. Pharmacol. 2008, 52:180-188.
31. Smith A.Q., Campbell J.L., Keys D.A., Fisher J.W. Rat tissue and blood partition coefficients for n-alkanes (C8 to C12). Int. J. Toxicol. 2005, 24:35-41.
32. Sweeney L.M., Gargas M.L., Strother D.E., Kedderis G.L. Physiologically based pharmacokinetic model parameter estimation and sensitivity and variability analyses for acrylonitrile disposition in humans. Toxicol. Sci. 2003, 71:27-40.
33. Tardif R., Lapare S., Charest-Tardif G., Brodeur J., Krishnan K. Physiologically-based pharmacokinetic modeling of a mixture of toluene and xylene in humans. Risk Anal. 1995, 15:335-342.
34. Thomas R.S., Bigelow P.L., Keefe T.J., Yang R.S. Variability in biological exposure indices using physiologically based pharmacokinetic modeling and Monte Carlo simulation. Am. Ind. Hyg. Assoc. J. 1996, 57:23-32.
35. USEPA, 2005. Approaches for the Application of Physiologically Based Pharmacokinetic (PBPK) Models and Supporting Data in Risk Assessment (External Review Draft 2005). Appendix 3: partition coefficients and metabolic rate constants for PBPK modeling of environmental chemicals. US Environmental Protection Agency, Washington, DC, EPA/600/R-05/043A, 2005. Available from: http://cfpub.epa.gov/ncea/CFM/recordisplay.cfm?deid=135427.
36. USEPA, 2009. Toxicological review of trichloroethylene (CAS No. 79-01-6). In support of summary information on the integrated risk information system (IRIS). External Review Draft. EPA/635/R-09/011A. Available from: http://cfpub.epa.gov/ncea/CFM/recordisplay.cfm?deid=215006.
37. USEPA, 2006. Approaches for the Application of Physiologically Based Pharmacokinetic (PBPK) Models and Supporting Data in Risk Assessment. National Center for Environmental Assessment. Office of Research and Development, US Environmental Protection Agency, Washington, DC. EPA/600/R-05/043F.
38. Yoon M., Madden M.C., Barton H.A. Extrahepatic metabolism by CYP2E1 in PBPK modeling of lipophilic volatile organic chemicals: impacts on metabolic parameter estimation and prediction of dose metrics. J. Toxicol. Environ. Health A 2007, 70:1527-1541.